Literature DB >> 21906479

Bioequivalence of topical clotrimazole formulations: an improved tape stripping method.

Natalie Rae Parfitt1, Michael Frederick Skinner, Charles Bon, Isadore Kanfer.   

Abstract

PURPOSE: Investigations were carried out to assess the use of tape stripping (TS) for the determination of bioequivalence of topical products containing 1% clotrimazole.
METHODS: The study design involved the establishment of an appropriate application time, which was determined by conducting a dose duration study. Subsequently, two bioequivalence studies were conducted: i) using the brand (Canesten Topical - 1% clotrimazole cream) as both the test and the reference product and ii) comparing Canesten cream with a gel product containing the same concentration of clotrimazole (1%). Each tape strip was individually analyzed for clotrimazole content using an HPLC method and Transepidermal Water Loss (TEWL) measurements were used to normalize the stratum corneum thicknesses between subjects.
RESULTS: The results of the TS investigations showed that, if the study is sufficiently powered, tape stripping may be used to determine bioequivalence according to the conventional bioequivalence limits of 0.8-1.25, as well as detect formulation differences between different clotrimazole products.
CONCLUSIONS: The data from this study provided compelling evidence that tape stripping has the necessary attributes and potential to be used as a tool for the bioequivalence assessment of topical clotrimazole and/or other topical formulations, thereby circumventing the need to undertake expensive and time-consuming clinical trials for such products. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906479     DOI: 10.18433/j3rp5k

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

Review 1.  Current challenges in bioequivalence, quality, and novel assessment technologies for topical products.

Authors:  Avraham Yacobi; Vinod P Shah; Edward D Bashaw; Eva Benfeldt; Barbara Davit; Derek Ganes; Tapash Ghosh; Isadore Kanfer; Gerald B Kasting; Lindsey Katz; Robert Lionberger; Guang Wei Lu; Howard I Maibach; Lynn K Pershing; Russell J Rackley; Andre Raw; Chinmay G Shukla; Kailas Thakker; Nathalie Wagner; Elizabeta Zovko; Majella E Lane
Journal:  Pharm Res       Date:  2014-01-07       Impact factor: 4.200

Review 2.  Pharmacokinetics-Based Approaches for Bioequivalence Evaluation of Topical Dermatological Drug Products.

Authors:  Sam G Raney; Thomas J Franz; Paul A Lehman; Robert Lionberger; Mei-Ling Chen
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

3.  Topical bioavailability of diclofenac from locally-acting, dermatological formulations.

Authors:  S F Cordery; A Pensado; W S Chiu; M Z Shehab; A L Bunge; M B Delgado-Charro; R H Guy
Journal:  Int J Pharm       Date:  2017-06-19       Impact factor: 5.875

4.  Novel imaging method to quantify stratum corneum in dermatopharmacokinetic studies: proof-of-concept with acyclovir formulations.

Authors:  Lisa M Russell; Richard H Guy
Journal:  Pharm Res       Date:  2012-07-19       Impact factor: 4.200

5.  Novel Approach for the Bioequivalence Assessment of Topical Cream Formulations: Model-Based Analysis of Tape Stripping Data Correctly Concludes BE and BIE.

Authors:  Deniz Ozdin; Isadore Kanfer; Murray P Ducharme
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

6.  Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence.

Authors:  Manfred Bodenlenz; Katrin I Tiffner; Reingard Raml; Thomas Augustin; Christian Dragatin; Thomas Birngruber; Denise Schimek; Gerd Schwagerle; Thomas R Pieber; Sam G Raney; Isadore Kanfer; Frank Sinner
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447

7.  Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal Drug.

Authors:  Leila Bastos Leal; Sarah F Cordery; M Begoña Delgado-Charro; Annette L Bunge; Richard H Guy
Journal:  Pharm Res       Date:  2017-01-17       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.